Literature DB >> 8353243

Group B streptococcal toxic shock-like syndrome: report of a case and purification of an associated pyrogenic toxin.

P M Schlievert1, J E Gocke, J R Deringer.   

Abstract

A patient with streptococcal toxic shock-like syndrome (TSLS) caused by Streptococcus agalactiae (group B Streptococcus) is described. The patient had all of the defining criteria for toxic shock syndrome (TSS), including fever, hypotension, erythematous rash, desquamation, and involvement of multiple organs. Neither Staphylococcus aureus nor group A streptococci were recovered, but vaginal and urine cultures yielded group B streptococci. The group B streptococcal isolate gave negative results in antibody tests for the production of TSS toxin 1, staphylococcal enterotoxins, and streptococcal scarlet fever toxins. However, the strain produced a novel pyrogenic toxin. This toxin, purified from culture fluids by ethanol precipitation, isoelectric focusing, and reverse-phase high-pressure liquid chromatography, had a molecular weight of 12,000 and an isoelectric point of approximately 7.0. The purified toxin was pyrogenic in rabbits, enhanced the susceptibility of the animals to lethal endotoxin shock, and caused the proliferation of rabbit splenocytes; these properties define pyrogenic toxins. When given to three rabbits via a subcutaneous miniosmotic pump, the toxin caused TSS-like symptoms ending in death. Three additional group B streptococcal strains from patients with TSLS were tested and were found to produce a toxin with similar properties.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353243     DOI: 10.1093/clinids/17.1.26

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Therapeutic Approaches to Streptococcal Toxic Shock Syndrome.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

2.  Group B Streptococcus necrotizing fasciitis: an emerging disease?

Authors:  C-H Wong; A Kurup; K-C Tan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-16       Impact factor: 3.267

Review 3.  Group B streptococcal toxic shock syndrome in an asplenic patient: case report and literature review.

Authors:  K D Sims; T D Barton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

4.  Toxic shock syndrome due to group C streptococci. A case report.

Authors:  S Natoli; C Fimiani; N Faglieri; L Laurenzi; A Calamaro; A M Frasca; E Arcuri
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

5.  Menaquinone analogs inhibit growth of bacterial pathogens.

Authors:  Patrick M Schlievert; Joseph A Merriman; Wilmara Salgado-Pabón; Elizabeth A Mueller; Adam R Spaulding; Bao G Vu; Olivia N Chuang-Smith; Petra L Kohler; John R Kirby
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

6.  Toxic shock syndrome: A rare complication to enhanced external counterpulsation.

Authors:  Peter Godsk Jørgensen; Jens Aage Lindberg; Ole May
Journal:  Can J Cardiol       Date:  2010-12       Impact factor: 5.223

Review 7.  Device-Associated Menstrual Toxic Shock Syndrome.

Authors:  Patrick M Schlievert; Catherine C Davis
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

8.  Major outbreak of toxic shock-like syndrome caused by Streptococcus mitis.

Authors:  Hong-Zhou Lu; Xin-Hua Weng; Bai Zhu; Haijing Li; You-Kuan Yin; Yong-Xin Zhang; David W Haas; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Molecular characterization of the cfb gene encoding group B streptococcal CAMP-factor.

Authors:  A Podbielski; O Blankenstein; R Lütticken
Journal:  Med Microbiol Immunol       Date:  1994-11       Impact factor: 3.402

Review 10.  Necrotizing fasciitis in captive juvenile Crocodylus porosus caused by Streptococcus agalactiae: an outbreak and review of the animal and human literature.

Authors:  E J Bishop; C Shilton; S Benedict; F Kong; G L Gilbert; D Gal; D Godoy; B G Spratt; B J Currie
Journal:  Epidemiol Infect       Date:  2007-04-20       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.